The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4115-4121

  Tascilar, Metin ^a   Rosty, Christophe ^a   Wilentz, Robb E ^a   Kern, Scott E ^a   Hruban, Ralph H ^a   Goggins, Michael ^a   Skinner, Halcyon G ^b   Sohn, Taylor ^e   Offerhaus, G Johan A ^e   Abrams, Ross A ^e   Cameron, John L ^e   Yeo, Charles J ^e   Adsay, Volkan ^e  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d HARPER UNIVERSITY HOSPITAL   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; SMAD PROTEIN; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLEEDING; CANCER SURVIVAL; FEMALE; GENE ISOLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMAD4 GENE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; CARCINOMA, DUCTAL, BREAST; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SURVIVAL RATE; TIME FACTORS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035671396     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Prognostic factors in ductal pancreatic cancer
2. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: Acceptable toxicity and suggestion of improved 1-year disease-free survival
3. Curative treatment for pancreatic neoplasms. Standard resection
4. Periampullary adenocarcinoma: Analysis of 5-year survivors
5. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience
6. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial
7. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
8. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group
9. Complete remission of nonresectable pancreatic cancer after infusional colloidal phosphorus-32 brachytherapy, external beam radiation therapy, and 5-fluorouracil: A preliminary report
10. Adjuvant therapy for pancreatic cancer: Back to the future
11. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors
12. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma
13. Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy
14. bax, but not bc1-2, influences the prognosis of human pancreatic cancer
15. Prognostic factors in resectable pancreatic cancer: P53 and Bc1-2
16. Overexpression of p53 protein in adenocarcinoma of the pancreas
17. K-ras oncogene activation in adenocarcinomas of the human pancreas: A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
18. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma
19. Progress in cancer genetics: Lessons from pancreatic cancer
20. DPC4, a candidate tumor-suppressor gene at 18q21.1
21. Signaling of transforming growth factor-β family members through smad proteins
22. Dpc4 protein in mucinous cystic neoplasms of the pancreas: Frequent loss of expression in invasive carcinomas suggests a role in genetic progression
23. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: Comparison with conventional ductal adenocarcinomas
24. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation
25. A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation
26. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients
27. Can we screen high-risk individuals to detect early pancreatic carcinoma?
28. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma
29. Analysis of p53, p21WAF1, and TGF-β1 in human ductal adenocarcinoma of the pancreas: TGF-β1 protein expression predicts longer survival
30. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor β signaling by targeting Smads to the ubiquitin-proteasome pathway
31. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression
32. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma
33. Targeted deletion of Smad4 shows it is required for transforming growth factor β and activin signaling in colorectal cancer cells
34. 1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: Phenotypes reversed by a tumorigenic mutation
35. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
36. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells